ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Mammogram AI Flags Hidden Heart Disease Risk 09/17/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded September 17, 2025. This episode summarizes 5 key cardiology studies on topics like vascular complications and smooth muscle cell proliferation. Key takeaway: Mammogram AI Flags Hidden Heart Disease Risk.
Article Links:
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. (Circulation)
Article 2: Predicting cardiovascular events from routine mammograms using machine learning. (Heart (British Cardiac Society))
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. (Heart (British Cardiac Society))
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. (JACC. Heart failure)
Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/
Featured Articles
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40955569
Summary: This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.
Article 2: Predicting cardiovascular events from routine mammograms using machine learning.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40957672
Summary: Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40957671
Summary: This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40956259
Summary: Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide’s benefits extended to both frail and non-frail patients, suggesting it’s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.
Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40769446
Summary: A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention.
Transcript
Today’s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.
Article number two. Predicting cardiovascular events from routine mammograms using machine learning. Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.
Article number three. Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.
Article number four. Frailty and Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction: Findings From the STEP-HFpEF Program. Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide’s benefits extended to both frail and non-frail patients, suggesting it’s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.
Article number five. PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention.
Thank you for listening. Don’t forget to subscribe.
Keywords
vascular complications, smooth muscle cell proliferation, photoplethysmography, mammography, neointimal hyperplasia, frailty, screening, smartphone application, stroke prevention, Heart Failure with Preserved Ejection Fraction, cardiovascular risk prediction, PDZ domain, Lectin-like Oxidized Low-Density Lipoprotein Receptor-1, semaglutide, TAX1BP3, machine learning, obesity, breast arterial calcification, deep learning, acute coronary syndrome, heart failure, prognosis, STEP-Heart Failure with Preserved Ejection Fraction trial, atrial fibrillation, major adverse cardiovascular events.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Mammogram AI Flags Hidden Heart Disease Risk 09/17/25 first appeared on Cardiology Today.
Article Links:
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. (Circulation)
Article 2: Predicting cardiovascular events from routine mammograms using machine learning. (Heart (British Cardiac Society))
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. (Heart (British Cardiac Society))
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. (JACC. Heart failure)
Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. (Heart rhythm)
Full episode page: https://podcast.explainheart.com/podcast/mammogram-ai-flags-hidden-heart-disease-risk-09-17-25/
Featured Articles
Article 1: TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40955569
Summary: This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.
Article 2: Predicting cardiovascular events from routine mammograms using machine learning.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40957672
Summary: Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.
Article 3: Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40957671
Summary: This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.
Article 4: Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.
Journal: JACC. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40956259
Summary: Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide’s benefits extended to both frail and non-frail patients, suggesting it’s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.
Article 5: PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial.
Journal: Heart rhythm
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40769446
Summary: A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention.
Transcript
Today’s date is September 17, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. TAX1BP3 Is a SUMOylated Nucleocytoplasmic Shuttling Protein and Protects Against Vascular Neointimal Hyperplasia. This Circulation study found that TAX1BP3, a SUMOylated protein, plays a protective role against neointimal hyperplasia, a major cause of vascular complications after arterial interventions. Overexpression of TAX1BP3 inhibited smooth muscle cell proliferation and migration, key processes in neointima formation, suggesting it could be a therapeutic target. The study highlights the potential of targeting PDZ domain-mediated protein interactions to improve long-term outcomes after vascular procedures.
Article number two. Predicting cardiovascular events from routine mammograms using machine learning. Researchers developed a deep learning algorithm to predict cardiovascular risk using routine mammography images. Analysis of mammograms was linked to hospitalization and death databases, showing that the algorithm could identify women at increased risk based on features like breast arterial calcification. This approach offers a novel opportunity to improve cardiovascular risk assessment in women during midlife screening.
Article number three. Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome. This prospective study in Heart found that elevated plasma levels of soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) in patients with acute coronary syndrome correlated with increased risk of developing heart failure, major adverse cardiovascular events, and left ventricular dysfunction. Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 levels may serve as a prognostic biomarker to identify high-risk patients after acute coronary syndrome. Targeting Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 could be a novel therapeutic avenue.
Article number four. Frailty and Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction: Findings From the STEP-HFpEF Program. Analysis of the STEP-Heart Failure with Preserved Ejection Fraction trial showed that semaglutide improved heart failure symptoms, physical limitations, and body weight in patients with obesity-related Heart Failure with Preserved Ejection Fraction, irrespective of frailty status. Semaglutide’s benefits extended to both frail and non-frail patients, suggesting it’s a valuable treatment option for this patient population. The study supports the use of semaglutide to improve outcomes in obese patients with Heart Failure with Preserved Ejection Fraction, even in the presence of frailty.
Article number five. PPG-based smartphone application vs usual care for atrial fibrillation screening: A European multicenter randomized trial. A European multicenter randomized trial evaluated the effectiveness of a smartphone application using photoplethysmography (PPG) for atrial fibrillation screening. The study found that the application with early intervention led to significantly higher detection rates of atrial fibrillation compared to the control group. This suggests that smartphone-based photoplethysmography is an effective tool for large-scale atrial fibrillation screening, potentially enabling earlier diagnosis and stroke prevention.
Thank you for listening. Don’t forget to subscribe.
Keywords
vascular complications, smooth muscle cell proliferation, photoplethysmography, mammography, neointimal hyperplasia, frailty, screening, smartphone application, stroke prevention, Heart Failure with Preserved Ejection Fraction, cardiovascular risk prediction, PDZ domain, Lectin-like Oxidized Low-Density Lipoprotein Receptor-1, semaglutide, TAX1BP3, machine learning, obesity, breast arterial calcification, deep learning, acute coronary syndrome, heart failure, prognosis, STEP-Heart Failure with Preserved Ejection Fraction trial, atrial fibrillation, major adverse cardiovascular events.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post Mammogram AI Flags Hidden Heart Disease Risk 09/17/25 first appeared on Cardiology Today.
More episodes of the podcast Cardiology Today
CRISPR-Cas9 Gene Editing for Lipids 11/11/25
11/11/2025
In God we trust